Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GSK5764227 |
| Synonyms | |
| Therapy Description |
GSK5764227 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CD276 (B7-H3) linked to a topoisomerase I inhibitor, which may induce apoptosis and inhibit proliferation of tumor cells expressing CD276 (B7-H3) (Cancer Res (2025) 85 (8_Supplement_2): CT195, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GSK5764227 | GSK 5764227|GSK-5764227|HS-20093|HS20093|HS 20093 | CD276 Antibody 21 | GSK5764227 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CD276 (B7-H3) linked to a topoisomerase I inhibitor, which may induce apoptosis and inhibit proliferation of tumor cells expressing CD276 (B7-H3) (Cancer Res (2025) 85 (8_Supplement_2): CT195, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07099898 | Phase III | Topotecan GSK5764227 | A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) | Recruiting | TUR | GBR | CAN | BRA | AUS | ARG | 3 |
| NCT06551142 | Phase I | GSK5764227 Topotecan | A Study of GSK5764227 in Participants With Advanced Solid Tumors | Recruiting | USA | GBR | FRA | ESP | CAN | ARG | 4 |
| NCT06885034 | Phase Ib/II | GSK5764227 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed | Recruiting | USA | SWE | POL | NOR | NLD | ITA | FRA | ESP | CAN | BRA | BEL | AUS | 2 |